Daptomycin use in neutropenic patients with documented gram-positive infections
- First Online:
- 756 Downloads
The goal of this study was to describe the outcomes associated with daptomycin treatment of documented gram-positive infections in patients with neutropenia.
All patients with neutropenia (≤500 cells/m3) and at least one documented gram-positive culture from 2006–2009 were identified from a retrospective, multicenter, and observational registry (Cubicin® Outcome Registry and Experience (CORE®)). Investigators assessed patient outcome (cured, improved, failed, nonevaluable) at the end of daptomycin therapy. All patients were included in the safety analysis.
The efficacy population had 186 patients; 159 (85 %) patients had either cure (n = 108, 58 %) or improved (n = 51, 27 %) as an outcome. Success rates (cure plus improved) by the lowest WBC during daptomycin were 98/116 (84 %) for ≤100 cells/m3 and 61/70 (87 %) for 101–499 cells/m3, P = 0.6. Most patients had cancer; 135/186 (73 %) had hematological malignancy; 26/186 (14 %) had solid tumors, and 9 (5 %) had both. One hundred fifty-six (84 %) patients received other antibiotics before daptomycin treatment; 82 % vancomycin, of which 31 % failed vancomycin. The most common infections were bacteremia (78 %), skin and skin structure infections (8 %), and urinary tract infections/pyelonephritis (6 %). The most common pathogens were vancomycin-resistant Enterococcus faecium (47 %), methicillin-resistant Staphylococcus aureus (20 %), and coagulase-negative staphylococci (19 %). The median (min, max) initial daptomycin dose was 6 mg/kg (3.6, 8.3). The median (min, max) daptomycin duration of therapy was 14 days (1, 86). Possibly related adverse events occurred in 12/209 patients (6 %), and 13 patients (6 %) discontinued daptomycin due to adverse event.
The results suggest that daptomycin appeared useful and well tolerated in neutropenic patients, and the degree of neutropenia did not affect daptomycin success rates. Comparative clinical trials are needed to confirm these findings.
KeywordsDaptomycin Neutropenia Staphylococcus aureus Enterococcus faecium
- 3.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–93PubMedCrossRefGoogle Scholar
- 6.Cometta A, Kern WV, de Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Gauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37(3):382–97Google Scholar
- 7.Feld R (1999) Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 29:503–507Google Scholar
- 9.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18–55PubMedCrossRefGoogle Scholar
- 10.Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325–7PubMedCrossRefGoogle Scholar
- 11.Kapadia M, Coyle E, Prince R, Rolston K (2005) Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16–19, 2005, Washington, DC. Abstract No. E-807Google Scholar
- 12.Mahajan SN, Shah JN, Hachem R, Tverdek F, Adachi JA, Mulanovich V, Rolston KV, Raad II, Chemaly RF (2012) Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 12(17):1329–1336CrossRefGoogle Scholar
- 14.Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD (2007) Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 51:1787–1794PubMedCrossRefGoogle Scholar
- 18.Hogan H, Raad I, Rolston K (2007) Daptomycin therapy for gram-positive infections in cancer patients. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy, March 31–April 3, 2007, Munich, Germany. Abstract No. P-1666Google Scholar
- 19.Hogan HL, Adachi JA, Coyle EA, Rolston KVI (2007) Daptomycin therapy of gram-positive infections (GPI) in pediatric cancer patients. Presented at: 14th International Symposia on Infections in the Immunocompromised Host, June 2007, Thessaloniki, GreeceGoogle Scholar
- 22.Rossetti JM, Thatikonda C, Shadduck RK, Sahovic E, Kaplan RB, Kennedy M, Lister J (2008) Daptomycin plus cefepime for moderate and high-risk febrile neutropenic patients with increased risk of gram-positive infection. Biol Blood Marrow Transplantation 14 (supplement):98Google Scholar
- 25.Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445–452PubMedCrossRefGoogle Scholar
- 31.Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA (2013) Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 57:261–26832PubMedCrossRefGoogle Scholar
- 36.Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R (2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51:1656–1660PubMedCrossRefGoogle Scholar
- 37.ZYVOX® (linezolid) (2008) [package insert]. New York, NY: Pharmacia & Upjohn: Division of Pfizer, IncGoogle Scholar
- 41.Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–51PubMedGoogle Scholar
- 43.Rolston KVI, Bodey GP (2006) Infections in patients with cancer. In: Kufe DW, Frei EI, Holland JF et al (eds) Cancer medicine, 7th edn. BC Decker, Inc., Hamilton, Ontario, Canada, pp 2222–2245Google Scholar